Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • CCR
    (1)
  • Cholecystokinin Receptor
    (1)
  • Others
    (5)
Filter
Search Result
Results for "

gastrin/cck-b

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    8
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Antibody Products
    1
    TargetMol | Antibody_Products
CCK-B Receptor Antagonist 2
T10707155412-88-7
CCK-B Receptor Antagonist 2 is a potent and orally active antagonist of Gastrin CCK-B (IC50: 0.43 nM). It also inhibits gastrin CCK-A activity (IC50: 1.82 μM).
  • Inquiry Price
6-8 weeks
Size
QTY
Sograzepide
YF476, YF 476, YM220, YM-220, Netazepide
T16906155488-25-8
Sograzepide (Netazepide) is an orally active, selective and highly potent gastrin CCK-B antagonist that inhibits gastrin CCK-A activity and pappalysin 2 expression in type 1 gastric neuroendocrine tumors, and can induce regression of type 1 gastric neuroendocrine tumors.
  • Inquiry Price
6-8 weeks
Size
QTY
YM022
T17274145084-28-2
YM022 is a highly effective and selective gastrin cholecystokinin (CCK)-B receptor antagonist. YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo. YM022 shows the Ki values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively.
  • Inquiry Price
6-8 weeks
Size
QTY
L-365260
L365260, L-365,260, L 365260
T22895118101-09-0
L-365260 is an orally available, selective and potent nonpeptide gastrin and cerebral cholecystokinin receptor (CCK-B) antagonist.L-365260 inhibits CCK-8S-induced increase in [Ca2+]i, blocks stress-induced hypersensitivity in viscera, and blocks the anti-exploratory effect of CCK-4.L-365260 has been used in the study of neurological Ojibwa and endocrine diseases.
  • Inquiry Price
6-8 weeks
Size
QTY
DA-3934
UNII-J353803KRG
T23946183176-50-3
DA-3934 has a high affinity for gastrin/CCK-B receptors and high selectivity over CCK-A receptors. DA-3934 and its methyl ester derivative inhibited pentagastrin-induced gastric acid secretion in rats in a dose-dependent manner.
  • Inquiry Price
8-10 weeks
Size
QTY
PD 136450
Cam1189,PD136450,Cam-1189,PD-136450,Cam 1189
T28331139067-52-0
Cholecystokinin type B receptor antagonist PD-136,450 is a partial secretory agonist in the stomach and a full agonist in the pancreas of the rat. Gastrin (cholecystokinin type B (CCK-B)) receptor antagonists may help to elucidate the physiological role o
  • Inquiry Price
10-14 weeks
Size
QTY
L-365260 hemihydrate
T62039
L-365260 hemihydrate is a selective, orally active non-peptide gastrin and brain cholecystokinin receptor (CCK-B) antagonist, demonstrating competitive interaction with guinea pig stomach gastrin and brain CCK receptors and exhibiting inhibition constants (Kis) of 1.9 nM and 2.0 nM, respectively.
  • Inquiry Price
10-14 weeks
Size
QTY
[Leu15]-Gastrin I human acetate(39024-57-2 Free base)
T8761L
[Leu15]-Gastrin I human acetate(39024-57-2 Free base) is a peptide. It acts through G protein-coupled receptors, known as cholecystokinin (CCK) or CCK-B receptor (CCK-BR).
  • Inquiry Price
Size
QTY